DrugPatentWatch Database Preview
Drugs in Development Information for Ketanserin
» See Plans and Pricing
What is the development status for investigational drug Ketanserin?
Ketanserin is an investigational drug.
There have been 8 clinical trials for Ketanserin.
The most recent clinical trial was a Phase 3 trial, which was initiated on March 1st 2011.
The most common disease conditions in clinical trials are Renal Insufficiency, Acute Kidney Injury, and Ulcer. The leading clinical trial sponsors are Gitte Moos Knudsen, Medical Centre Leeuwarden, and University Hospital, Basel, Switzerland.
There is one US patent protecting this investigational drug and eleven international patents.
Summary for Ketanserin
| US Patents | 1,346 |
| International Patents | 11,819 |
| US Patent Applications | 1,937 |
| WIPO Patent Applications | 2,274 |
| Japanese Patent Applications | 5 |
| Clinical Trial Progress | Phase 3 (2011-03-01) |
| Vendors | 76 |
Recent Clinical Trials for Ketanserin
| Title | Sponsor | Phase |
|---|---|---|
| Effect of Ketanserin After LSD Administration | University Hospital, Basel, Switzerland | Phase 1 |
| Role of the Serotonin 5-HT2A Receptor in LSD-induced Altered States of Consciousness (LDR-Study) | Matthias Liechti | Early Phase 1 |
| The Neurobiological Effect of 5-HT2AR Modulation | Gitte Moos Knudsen | Phase 1 |
Clinical Trial Summary for Ketanserin
Top disease conditions for Ketanserin
Top clinical trial sponsors for Ketanserin
US Patents for Ketanserin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Ketanserin | Start Trial | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder | Axovant Sciences GmbH (Basel, CH) | Start Trial |
| Ketanserin | Start Trial | Topical gel compositions including polycaprolactone polymer and methods for enhancing the topical application of a benefit agent | Johnson & Johnson Consumer Inc. (Skillman, NJ) | Start Trial |
| Ketanserin | Start Trial | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases | ACADIA PHARMACEUTICALS INC. (San Diego, CA) | Start Trial |
| Ketanserin | Start Trial | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease | Axovant Sciences GmbH (Basel, CH) | Start Trial |
| Ketanserin | Start Trial | Methods and systems for manufacturing a tablet | Massachusetts Insititute of Technology (Cambridge, MA) | Start Trial |
| Ketanserin | Start Trial | Pyrimidines as sodium channel blockers | Purdue Pharma L.P. (Stamford, CT) | Start Trial |
| Ketanserin | Start Trial | Substituted heteroaryl compounds and methods of use | CALITOR SCIENCES, LLC (Newbury Park, CA) SUNSHINE LAKE PHARMA CO., LTD. (Dongguan, Guangdong, CN) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Ketanserin
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Ketanserin | Argentina | AR104982 | 2035-06-12 | Start Trial |
| Ketanserin | Australia | AU2016276966 | 2035-06-12 | Start Trial |
| Ketanserin | Canada | CA2989343 | 2035-06-12 | Start Trial |
| Ketanserin | China | CN109562085 | 2035-06-12 | Start Trial |
| Ketanserin | European Patent Office | EP3307260 | 2035-06-12 | Start Trial |
| Ketanserin | Hong Kong | HK1245660 | 2035-06-12 | Start Trial |
| Ketanserin | Israel | IL256231 | 2035-06-12 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
